EXOSOME-TARGETING BISPECIFIC ANTIBODIES

The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 ("PD-L1") as a second exosome-associated protein. These bispecific antibodies ca...

Full description

Saved in:
Bibliographic Details
Main Authors MORIN MICHAEL J, ROBINSON MATTHEW K
Format Patent
LanguageChinese
English
Published 21.09.2021
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 ("PD-L1") as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by targeting tumor-cell derived exosomes that inhibit T cell activation. Therefore, bispecific antibodies of the invention can be used in methods for treating cancers. 本文所述的发明涉及双特异性抗体，其能够通过特异性结合第一外泌体相关蛋白和作为第二外泌体相关蛋白的程序性死亡配体-1("PD-L1")来选择性地靶向外泌体。这些双特异性抗体可以通过靶向抑制T细胞活化的肿瘤细胞来源的外泌体来破坏对免疫细胞的抗肿瘤活性的抑制。因此，本发明的双特异性抗体可用于治疗癌症的方法中。
Bibliography:Application Number: CN201980081663